Literature DB >> 29218658

Hypopharyngeal multichannel intraluminal impedance leads to the promising outcome of antireflux surgery in Japanese population with laryngopharyngeal reflux symptoms.

Takeshi Suzuki1, Yosuke Seki2, Yoshitaka Okamoto1, Toshitaka Hoppo3.   

Abstract

BACKGROUND: Clinical characteristics of laryngopharyngeal reflux (LPR) in Japanese population remain unclear, and its treatment outcome is suboptimal. The objectives of this study were to evaluate Japanese patients with LPR symptoms using hypopharyngeal multichannel intraluminal impedance (HMII) and to assess the outcome of antireflux surgery (ARS).
METHODS: Subjects included patients who had LPR symptoms for > 12 weeks or laryngoscopic findings suggestive of LPR and underwent laryngoscopy and esophageal testing including HMII. Abnormal proximal exposure (APE) was defined as LPR ≥ 1/day and/or full column reflux (FCR) (reflux 2 cm distal to the upper esophageal sphincter) ≥ 5/day on HMII. Patients with APE were offered ARS and the outcome of ARS was objectively assessed using Reflux Symptom Index (RSI).
RESULTS: From July 2015 to September 2016, 52 patients with LPR symptoms (28 men, 24 women, median BMI 22.3) underwent HMII, and 38 patients (73%) had APE. Of them, 29 (76%) patients were not obese (BMI < 25) and 19 (50%) patients had a negative DeMeester score. Approximately one-third of LPR and FCR events were non-acid in the distal esophagus. A positive symptom-association probability was seen only in 18 patients (35%). Mild esophagitis and hiatal hernia were found in 5 (10%) and 23 (48%) patients, respectively. All 12 patients (100%) who had undergone ARS were able to discontinue PPI and had a significant improvement in the RSI scores postoperatively (22.9 ± 10.0 vs. 6.8 ± 6.8, p < .001).
CONCLUSIONS: APE was frequently observed in Japanese patients with LPR symptoms. Obesity and esophagitis were uncommon in this population. Since a large number of patients with APE had negative DeMeester score and proximal reflux events were often non-acid, a conventional pH monitoring is insufficient. HMII is crucial to evaluate patients with LPR symptoms as the documentation of APE is a key for successful outcome of ARS.

Entities:  

Keywords:  Abnormal proximal exposure; Antireflux surgery; Hypopharyngeal multichannel intraluminal impedance; Japanese; Laryngopharyngeal reflux

Mesh:

Year:  2017        PMID: 29218658     DOI: 10.1007/s00464-017-5940-z

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  40 in total

1.  Defective triggering of secondary peristalsis in patients with non-erosive reflux disease.

Authors:  Katsuhiko Iwakiri; Yoshinori Hayashi; Makoto Kotoyori; Yuriko Tanaka; Noriyuki Kawami; Hirohito Sano; Kaiyo Takubo; Choitsu Sakamoto; Richard H Holloway
Journal:  J Gastroenterol Hepatol       Date:  2007-12       Impact factor: 4.029

2.  Regional oesophageal sensitivity to acid and weakly acidic reflux in patients with non-erosive reflux disease.

Authors:  S Emerenziani; M Ribolsi; D Sifrim; K Blondeau; M Cicala
Journal:  Neurogastroenterol Motil       Date:  2008-10-07       Impact factor: 3.598

3.  Laryngeal pseudosulcus as a predictor of laryngopharyngeal reflux.

Authors:  C Hickson; C B Simpson; R Falcon
Journal:  Laryngoscope       Date:  2001-10       Impact factor: 3.325

4.  Body-mass index and symptoms of gastroesophageal reflux in women.

Authors:  Brian C Jacobson; Samuel C Somers; Charles S Fuchs; Ciarán P Kelly; Carlos A Camargo
Journal:  N Engl J Med       Date:  2006-06-01       Impact factor: 91.245

5.  Association between reflux oesophagitis and features of the metabolic syndrome in Japan.

Authors:  F Moki; M Kusano; M Mizuide; Y Shimoyama; O Kawamura; H Takagi; T Imai; M Mori
Journal:  Aliment Pharmacol Ther       Date:  2007-10-01       Impact factor: 8.171

6.  Obesity as a risk factor for GERD in Japan.

Authors:  Masahiro Sakaguchi; Hiroshi Oka; Takashi Hashimoto; Yutaka Asakuma; Miyuki Takao; Goki Gon; Makoto Yamamoto; Yoshihisa Tsuji; Norihiko Yamamoto; Mamoru Shimada; Kyowon Lee; Kiyoshi Ashida
Journal:  J Gastroenterol       Date:  2008-02-24       Impact factor: 7.527

7.  Antireflux surgery in patients with chronic cough and abnormal proximal exposure as measured by hypopharyngeal multichannel intraluminal impedance.

Authors:  Toshitaka Hoppo; Yoshihiro Komatsu; Blair A Jobe
Journal:  JAMA Surg       Date:  2013-07       Impact factor: 14.766

Review 8.  Laryngopharyngeal reflux is different from classic gastroesophageal reflux disease.

Authors:  James A Koufman
Journal:  Ear Nose Throat J       Date:  2002-09       Impact factor: 1.697

9.  Validity and reliability of the reflux symptom index (RSI).

Authors:  Peter C Belafsky; Gregory N Postma; James A Koufman
Journal:  J Voice       Date:  2002-06       Impact factor: 2.009

Review 10.  Meta-analysis of the efficacy of proton pump inhibitors for the symptoms of laryngopharyngeal reflux.

Authors:  C Liu; H Wang; K Liu
Journal:  Braz J Med Biol Res       Date:  2016-07-04       Impact factor: 2.590

View more
  2 in total

1.  Simultaneous Evaluation of Laryngopharyngeal Reflux and Swallowing Function Using Hypopharyngeal Multichannel Intraluminal Impedance Measurements in Neurologically Impaired Patients.

Authors:  Daisuke Masui; Suguru Fukahori; Naoki Hashizume; Shinji Ishii; Naruki Higashidate; Saki Sakamoto; Shiori Tsuruhisa; Hirotomo Nakahara; Nobuyuki Saikusa; Yoshiaki Tanaka; Minoru Yagi
Journal:  J Neurogastroenterol Motil       Date:  2021-04-30       Impact factor: 4.924

2.  Reflux-related Extraesophageal Symptoms Until Proven Otherwise: A Direct Measurement of Abnormal Proximal Exposure Based on Hypopharyngeal Multichannel Intraluminal Impedance as a Reliable Indicator for Successful Treatment Outcomes.

Authors:  Takeshi Suzuki; Yosuke Seki; Tomoaki Matsumura; Makoto Arai; Toyoyuki Hanazawa; Yoshitaka Okamoto; Haruhiko Suzuki; Kazunori Kasama; Akiko Umezawa; Yoshimoti Kurokawa; Toshitaka Hoppo
Journal:  J Neurogastroenterol Motil       Date:  2022-01-30       Impact factor: 4.924

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.